Midatech Pharma PLC Form 8 (OPD) (Midatech Pharma plc) (7369L)
May 04 2020 - 2:00AM
UK Regulatory
TIDMMTPH
RNS Number : 7369L
Midatech Pharma PLC
04 May 2020
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Midatech Pharma plc ("Midatech")
(b) Owner or controller of interests and short positions disclosed, if different N/A
from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the
trustee(s),
settlor and beneficiaries must be named.
---------------------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form Midatech Pharma plc
relates:
Use a separate form for each offeror/offeree
---------------------------------
(d) Is the discloser the offeror or the offeree? OFFEROR / OFFEREE
---------------------------------
(e) Date position held: 1 May 2020
The latest practicable date prior to the disclosure
---------------------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures YES / NO / N/A
in respect If YES, specify which:
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
---------------------------------
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates
Class of relevant security:
Interests Short positions
------------ ------------------
Number % Number %
-------- ------------- ---
(1) Relevant securities owned and/or controlled: n/a n/a
-------- ------------- ---
(2) Cash-settled derivatives: n/a n/a
-------- ------------- ---
(3) Stock-settled derivatives (including options) and agreements to purchase/sell: n/a n/a
-------- ------------- ---
n/a n/a
TOTAL:
-------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
Class of relevant security in relation to which subscription right exists: n/a
Details, including nature of the rights concerned and relevant percentages: n/a
----
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE
Details of any interests, short positions and rights to subscribe (including directors' and
other employee options) of any person acting in concert with the party to the offer making
the disclosure:
Interest of Midatech Directors and connected advisers in Midatech shares: Name Number of Shares % of issued share
capital
Rolf Stahel 53,853 0.23
----------------- ------------------
Stephen Stamp 50,000 0.21
----------------- ------------------
Sijmen De Vries 26,242 0.11
----------------- ------------------
Simon Turton 55,325 0.24
----------------- ------------------
Interest of Midatech Directors in warrants over Midatech shares: Name Number of Warrants Exercise price Expiry date
Rolf Stahel 23,856 GBP10.00 26/02/2022
------------------- --------------- -----------
Sijmen De Vries 21,345 GBP10.00 26/02/2022
------------------- --------------- -----------
Simon Turton 41,855 GBP10.00 26/02/2022
------------------- --------------- -----------
Interest of Midatech Directors in options over Midatech shares: Name No. of Exercise Vesting date Expiry date
options price
Stephen Stamp 50,000 GBP1.05 20,000 if >$20m 02/10/2029
raised before
08/09/20, 7,500
on 09/09/20,
1,875 each
of 12 quarters
ending 09/12/23
--------- --------- ------------------- ------------
Sijmen de Vries 200 GBP83.80 Vested 20/04/2022
--------- --------- ------------------- ------------
Sijmen de Vries 500 GBP1.50 Based on share 30/06/2024
price:
50% at GBP106.20;
25% at GBP274.40;
25% at GBP377.20
--------- --------- ------------------- ------------
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer making the disclosure or any person acting
in concert with it:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer making the disclosure, or any person acting in concert with it, and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) YES/ NO
Supplemental Form 8 (SBL) YES/ NO
--------
Date of disclosure: 4 May 2020
Contact name: Stephen Stamp
CEO/CFO
-------------------
Telephone number: +44 (0)1235 888300
-------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's disclosure requirements on
+44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FEESSFFEDESSEFI
(END) Dow Jones Newswires
May 04, 2020 02:00 ET (06:00 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024
